Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study
Sanofi
Sikander Ailawadhi; Ivan Špička; Andrew Spencer; Jin Lu; Albert Oriol; Silvia Ling; Fredrik Schjesvold; Alejandro Berkovits; Marek Hus; Chunrui Li; Meletios-Athanasios Dimopoulos; Péter Rajnics; Sevgi Kalayoğlu Beşışık; Vania Hungria; Maria Del Rosario Custidiano; Gurdeep Parmar; Xavier Leleu; Fei Li; Claudio Cerchione; Cesar Gomez; Tadao Ishida; Maria Victoria Mateos; Tondre T Buck; Richard LeBlanc; Jiří Minařík; Hartmut Goldschmidt; Rick Zhang; Dorothée Sémiond; Florence Suzan; Maya Stefanova-Urena; Victorine Koch; Philippe Moreau